Toward a Melanoma Dendritic Cell Vaccine using Neoantigens

In April 2015, the group published in Science, a therapy with dendritic cells sensitized with neoantigens that are mutated peptides derived from melanomas, which are patient-specific. These mutations are missense that is, generated by changing a nucleotide, causing the appearance of a codon encoding a different amino acid, a protein product that the immune system recognizes as foreign.